Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Nivolumab for High Risk Oral Premalignant Lesions
NCT05327270Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2022
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in Oral Precancerous Lesions, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate at 1 year and Safety and Tolerability at 1 year. Started Sep 2022; status: active, not recruiting.
02
Drugs
03
Conditions
Oral Precancerous Lesions
Beyond the preview
Go deeper on NCT05327270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327270.